1752 | 南光 - Stock Value & PE Ratio Analysis

3

24

15

Good Growth

AI analysis rates 1752 with a higher value score of 4.
It is mainly due to adequate operating cash flow.
Over the past 3 months, 1752 has maintained a consecutive value rating of 4.0, close to the rating of 4.3 over the past 3 years, indicating stable enterprise value.
Compared to all stocks in the Biotech. & Medical sector, 1752 has a medium value rating.

1752 Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/05/09 (Weekly Update)

1752 Financial Forecast

Unit : TWD

Update to 2025/5/13 (Quarterly Update)

1752 Earnings Table

Unit : TWD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.71	31.5%	-	579.48M	9.7%	-	12.4%
2024Q4	0.85	350%	49.1%	579.21M	12.2%	1.3%	14.9%
2024Q3	0.86	87%	50.9%	579.21M	7.8%	1.3%	10%
2024Q2	0.44	-52.2%	-	512.3M	-2.2%	-	8.6%
2024Q1	0.54	-41.9%	-	528.47M	-7.8%	-	10.3%

Update to 2025/5/13 (Quarterly Update)

1752 Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

1752 Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of 1752 from 2009/08 till Now

8.67%
Cumulative Return: 0.54%
Annual Return: 15.36%
Volatility: 0.04
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from August, 2009 to May, 2025. (Total Trades: 1)